Latest / Pharmacy Podcast Network / Treating Chronic Itch: Beyond Antihistamines | Geriatric Pharmacy Focus
Transcript
- 0:06Speaker 1: You are listening to the Pharmacy Podcast Network.
- 0:21Speaker 2: We have an aging population taking more medications than ever before.
- 0:25Speaker 2: On this podcast, I will interview experts in geriatric medicine
- 0:29Speaker 2: to gain insights so we can provide optimal care to
- 0:31Speaker 2: patients in their golden ears. I'm your host, Doctor Tammar Ruggles,
- 0:34Speaker 2: and this is the Geriatric Pharmacy Focus. Hello everyone, and
- 0:41Speaker 2: welcome back to the Geriatric Pharmacy Focus. So today we're
- 0:45Speaker 2: going to be talking about chronic itch because with my
- 0:48Speaker 2: older adults, how many times have I seen them have
- 0:51Speaker 2: chronic IgE or a diagnosis of chronic IgE and what
- 0:54Speaker 2: is thrown.
- 0:55Speaker 1: At them as an antihistony. And so a couple of
- 0:58Speaker 1: years ago at the America Society of Consultant Pharmacist meeting,
- 1:02Speaker 1: I went to a talk on chronic itch by doctor
- 1:06Speaker 1: Laura Meyer Hunko.
- 1:08Speaker 3: And she titled it Itch Please, and.
- 1:11Speaker 1: It was so informative about chronic itch, the causes, the prevalence,
- 1:17Speaker 1: the treatment that I thought this would be a good
- 1:19Speaker 1: thing to share because it's not talked about a lot,
- 1:21Speaker 1: but it's prevalent in our older adults and there's a
- 1:24Speaker 1: wide variety of treatment options and that's not always an antihistamine.
- 1:27Speaker 1: So I would like to welcome our guest, doctor Laura.
- 1:30Speaker 1: She's a clinical pharmacist and assistant professor at the UIC
- 1:34Speaker 1: College of Pharmacy in Rockford, Illinois. She's also the editor
- 1:37Speaker 1: in chief of the Journal of Pain and Palliative Care Pharmacotherapy.
- 1:41Speaker 1: And if you've been listening to this podcast when it
- 1:44Speaker 1: was formerly the LTC Pharmacy Podcast, Scott and I had
- 1:47Speaker 1: her on as a guest about a year ago on
- 1:50Speaker 1: Opioid Stewardship, which is a great episode, so please tune
- 1:54Speaker 1: in if you haven't to that episode. But welcome back
- 1:56Speaker 1: to the podcast, doctor Laura, and tell us what is
- 1:59Speaker 1: new with you? We recorded a year ago.
- 2:02Speaker 4: Well, it's hard to believe it was a year ago.
- 2:04Speaker 4: It feels a little bit longer since I'm a new
- 2:06Speaker 4: mom and kind of you in the trenches with that.
- 2:09Speaker 4: He's going to be eleven months next week. But professionally,
- 2:13Speaker 4: something that's new that I'm excited about is a special
- 2:16Speaker 4: issue of the journal is going to be released. It's
- 2:18Speaker 4: the first one that I've been the editor for and
- 2:21Speaker 4: I think it's going to be an influential issue for
- 2:25Speaker 4: many pharmacists that are trying to expand their toolkit, which
- 2:29Speaker 4: is kind of the emphasis of today's talk too, about
- 2:31Speaker 4: expanding our toolkit beyond anaistamines. So this special issue is
- 2:35Speaker 4: integrative approaches to pain and palliative care and going beyond
- 2:40Speaker 4: pharmaco therapy. So I have invited commentaries from pharmacists and
- 2:45Speaker 4: also non pharmacists that are exploring integrative approaches and expanding
- 2:49Speaker 4: our pharmaco therapy toolkit beyond drug therapy. So it's been
- 2:54Speaker 4: a long time in coming to kind of get this
- 2:56Speaker 4: polished off. We get one more article to get through
- 2:58Speaker 4: production and then it's going to be least so new baby,
- 3:02Speaker 4: new special issue.
- 3:03Speaker 3: Oh my goodness, that's exciting.
- 3:05Speaker 1: Where can we find the special issue?
- 3:08Speaker 4: So it's the Journal of Pain and Palide of Care
- 3:09Speaker 4: pharmaco Therapy. I will be posting it on LinkedIn when
- 3:13Speaker 4: once it comes out, so it should be by the
- 3:16Speaker 4: end of October. It will be released, so you can
- 3:20Speaker 4: sign up to get the print issue or otherwise the
- 3:24Speaker 4: electronic issue.
- 3:25Speaker 3: So the any editorial piece in the journal will be
- 3:28Speaker 3: free access.
- 3:28Speaker 4: The rest requires, you know, some sort of electronic access
- 3:31Speaker 4: or purchasing of the article.
- 3:33Speaker 3: But I'm going to.
- 3:34Speaker 4: Try to announce it, you know, far and wide because
- 3:38Speaker 4: all the work that went into that when it when
- 3:40Speaker 4: it is released.
- 3:41Speaker 1: But oh that's going to be I'm going to yes,
- 3:43Speaker 1: and if it's if it's out when this episode drops,
- 3:46Speaker 1: I'll put a link in the show notes so you
- 3:48Speaker 1: guys can go purchase a copy. I'm sure it will
- 3:50Speaker 1: be worth it. So well, today we're going to talk
- 3:52Speaker 1: about chronic itch and so at your CE session, like
- 3:55Speaker 1: I say, I just learned so much I thought it
- 3:57Speaker 1: would be valuable. So to start us off, tell us
- 4:00Speaker 1: how chronic it is diagnosed and how prevalent it is
- 4:03Speaker 1: in our older adults.
- 4:05Speaker 4: So I think that's an important thing to distinguish when
- 4:07Speaker 4: we're we're looking at our patients that you know, prescribing
- 4:10Speaker 4: anhistamine are dealing with parritis. Is kind of distinguishing whether
- 4:14Speaker 4: this is a cute pritis or chronic pridis. And it's
- 4:18Speaker 4: it seems kind of arbitrary, but it's a six week marker.
- 4:20Speaker 4: So if it's less than six weeks, it's considered acute
- 4:24Speaker 4: and a que paridis could be Hissamy mediated. But then
- 4:28Speaker 4: when it's chronic and so meaning greater than six weeks,
- 4:31Speaker 4: it's likely not histamine mediated, yet we're still throwing in
- 4:34Speaker 4: histamines at these these folks. And so chronic itage is
- 4:38Speaker 4: actually highly prevalent in older adults because of skin changes
- 4:41Speaker 4: in the skin as they age, and also age related changes,
- 4:45Speaker 4: but also disease accumulation of disease like neuropathic conditions. So
- 4:49Speaker 4: it's thought that like this different depending on what literature
- 4:52Speaker 4: you look at. But so older adults are greater than
- 4:54Speaker 4: sixty five, it's not that maybe fifty percent of them
- 4:57Speaker 4: have chronic pridis at some point in their life, and
- 5:00Speaker 4: then one third of nursing home patients we'll have chronic pridis.
- 5:03Speaker 4: And then the weird thing, and this is really something
- 5:06Speaker 4: that we often struggle with, is this chronic pridus of
- 5:10Speaker 4: unknown idiology. This is a refractory condition that we throw
- 5:14Speaker 4: different agents at it, and it is just still there.
- 5:17Speaker 4: And older adults are actually, you know, the group with
- 5:21Speaker 4: probably the greatest prevalence of chronic pridis of unknown origin.
- 5:25Speaker 4: So you know, we're kind of up a creek with
- 5:28Speaker 4: our older adults and prietis and these figures are kind of,
- 5:33Speaker 4: you know, a little eye opening.
- 5:34Speaker 1: I think, yeah, I mean, fifty percent we'll experience it
- 5:38Speaker 1: in their lifetime that's huge, and so yeah, you kind
- 5:42Speaker 1: of talked about those why does it increase with age
- 5:45Speaker 1: while our skin changes as we age, we have more
- 5:48Speaker 1: chronic disease states, So several reasons why our older adults
- 5:52Speaker 1: are so prone to that itching greater than six weeks
- 5:55Speaker 1: or preritis. So I feel like one of the areas
- 5:58Speaker 1: that we can really provide value as pharmacists is identifying
- 6:03Speaker 1: causes of itch, but especially identifying medication causes of chronic itch.
- 6:08Speaker 1: Can you tell us some of those medications that cause itch.
- 6:12Speaker 4: So with the medications that can cause itch, if you
- 6:15Speaker 4: look at published literature on it, and many of them
- 6:17Speaker 4: are case reports, there is an astonishing number of medications
- 6:21Speaker 4: that can cause itch. But kind of the two largest
- 6:25Speaker 4: kind of ideologies of why medications would cause itch is
- 6:28Speaker 4: due to drug hypersensitivity reaction. So you're thinking antibiotics or antimicrobials,
- 6:34Speaker 4: there could be an allergic response to that which would
- 6:37Speaker 4: then cause skin changes. Another large reason why certain medications
- 6:44Speaker 4: may cause itching is due to colistatic liver injury. So
- 6:49Speaker 4: colistatic disease of the liver is also a major cause
- 6:54Speaker 4: of chronic itching, and so drugs that may cause or
- 6:59Speaker 4: contribute to injury to the liver such as you know,
- 7:03Speaker 4: amiodorone or other medications. You know, so sometimes even antibiotics
- 7:07Speaker 4: can cause colostatic liver injury.
- 7:10Speaker 3: Then that could cause itching.
- 7:12Speaker 4: And then some other medications that may have another mechanism
- 7:16Speaker 4: for itching would be like ACE inhibitors because of increased
- 7:18Speaker 4: levels of braided cainine.
- 7:20Speaker 3: And then the.
- 7:21Speaker 4: Major category of medications that I think about that cause
- 7:25Speaker 4: itching are opioids. Okay, So opioids have actually two mechanisms
- 7:31Speaker 4: that can cause itching, a peripheral and central. And that's
- 7:34Speaker 4: actually kind of funny because when you look at various
- 7:36Speaker 4: chronic diseases that can cause itching, they also also have a.
- 7:40Speaker 3: Central plus peripheral mechanisms.
- 7:42Speaker 4: So we often think that opioids cause itching through a
- 7:45Speaker 4: peripheral mechanism with release of histamine.
- 7:48Speaker 3: That may be the case for some some.
- 7:50Speaker 4: Opioids like morphine and codine, But then why does fentanyl
- 7:54Speaker 4: cause itching, especially when given as a spinal fensanyl Why
- 7:58Speaker 4: does that cause itching when it doesn't actually cause histamine release.
- 8:01Speaker 3: So the major mechanism of.
- 8:03Speaker 4: Opioid mediated itching is through mwopioid.
- 8:07Speaker 3: Receptor and Kappa receptor and balance.
- 8:10Speaker 4: That's also thought to be the mechanism behind a central
- 8:14Speaker 4: mechanism behind.
- 8:17Speaker 1: It.
- 8:17Speaker 3: Pride is due to colostasis.
- 8:19Speaker 4: So it's challenging to figure out what medications may be contributing,
- 8:23Speaker 4: and many of them could be according to case reports.
- 8:26Speaker 4: And that's kind of the literature quality that we're dealing with.
- 8:30Speaker 4: So kind of doing a good medication history and kind
- 8:33Speaker 4: of using the temporal relationship between when the itching developed
- 8:37Speaker 4: and maybe when a new medication was started.
- 8:40Speaker 3: But it can be very challenging.
- 8:42Speaker 4: But that's why pharmacists need to be involved to kind
- 8:44Speaker 4: of do the detective.
- 8:46Speaker 1: Work on this. Yeah, I can see, you know how
- 8:49Speaker 1: that could be challenging because think of how many of
- 8:51Speaker 1: our older adults have chronic itche but also chronic pain.
- 8:56Speaker 1: I mean you see it all the time that they're
- 8:58Speaker 1: on some sort of void for chronic pain. And also
- 9:02Speaker 1: ACE inhibitors are so common too, so plus the itching.
- 9:05Speaker 1: So I can see how it would be yes detective
- 9:08Speaker 1: work to go back and see when did the itch start,
- 9:11Speaker 1: when did the medication start? And it is it frequent
- 9:16Speaker 1: that the medication would be started and then the itch
- 9:18Speaker 1: would start soon after.
- 9:20Speaker 4: Well that's such a good question because you know if
- 9:22Speaker 4: you're talking about hypersensitivity reactions that can be acute and delay,
- 9:26Speaker 4: so it can be challenging to find the temporal relationship.
- 9:30Speaker 3: But if it is a medication that could be deprescribed.
- 9:34Speaker 4: Then do a trial deprescribing and see if it improves.
- 9:39Speaker 4: But I think even a larger factor beyond just medications
- 9:42Speaker 4: and old adults it contributes to itch that we should
- 9:44Speaker 4: address all the.
- 9:45Speaker 3: Time, is dry skin.
- 9:47Speaker 4: Right, So that's why some sometimes you'll see like literature
- 9:51Speaker 4: suggesting that diuretics and volume deplets can cause itchet, and
- 9:56Speaker 4: I wonder is it something related to the medication itself
- 9:59Speaker 4: or is it just.
- 9:59Speaker 3: Through de hydration?
- 10:01Speaker 4: Right, and then the whole ball of wax with a
- 10:04Speaker 4: dehydrated individual, dehydrated skin, et cetera, So it gets its
- 10:08Speaker 4: snowballs pretty quickly.
- 10:10Speaker 3: You have an exact answer in terms of when the
- 10:13Speaker 3: itching develops.
- 10:15Speaker 4: With opioids, it would developed acutely, so at least there's
- 10:18Speaker 4: a greater and easier temporal relationship there. Okay, well that's helpful, So.
- 10:25Speaker 1: It is helpful I think with so with chronic itch,
- 10:29Speaker 1: it's not histamine, it could be medications. What are some
- 10:32Speaker 1: other causes of the chronic itching?
- 10:35Speaker 4: So when you're thinking about chronic edge, I think the
- 10:38Speaker 4: first thing that you want to decide is whether it's
- 10:41Speaker 4: occurring on inflame skin or non inflame skin, and that
- 10:45Speaker 4: can be difficult if you're not having a face to
- 10:47Speaker 4: face assessment with a patient. But also because people scratch
- 10:50Speaker 4: and then the skin does get altered and does get inflamed.
- 10:54Speaker 4: But beyond the acute and chronic, it's important to know
- 10:58Speaker 4: what the skin look like, you know, at the time
- 11:00Speaker 4: the itching began at because if it was chronic itching,
- 11:06Speaker 4: but the skin has been inflames, and that's likely some
- 11:08Speaker 4: sort of dermatological condition that needs to be managed with
- 11:12Speaker 4: specialty care, you know, imomodulators, biologics, et cetera. So getting
- 11:16Speaker 4: a referral to dermatology. Now, if the itching is chronic
- 11:20Speaker 4: and it is occurring on non inflamed skin, then we
- 11:24Speaker 4: have things that could be happening essentrally. So one such
- 11:29Speaker 4: category is called neurogenic, which basically means the origin of
- 11:33Speaker 4: the itching is probably primarily central, though there could be
- 11:37Speaker 4: some peripheral processing also, but it's not due to any
- 11:40Speaker 4: damage to the nervous system, So it's neurogenic.
- 11:43Speaker 3: So due to the accumulation of you.
- 11:46Speaker 4: Know, endogenous substances that accumulate and cause changes to the
- 11:52Speaker 4: adages opioid system and dogena, serotonin system, you name it.
- 11:56Speaker 3: That then propagates this chronic itch.
- 12:00Speaker 4: And then another cause of itch that could be a
- 12:04Speaker 4: cause of chronic non inflamed skin itch is a neuro
- 12:08Speaker 4: neuropathic so due to you know, periphyle diabetic neuropathy, there
- 12:12Speaker 4: can be you know, a localized itch on non inflamed skin.
- 12:18Speaker 4: The discibution between localized and generalize is also helpful not
- 12:21Speaker 4: only for ideology but also for treatments. So even in
- 12:26Speaker 4: neurog for neurogenic types of chronic parritis, it tends to
- 12:30Speaker 4: be more generalized. So neurogenic conditions that would cause neurogenic
- 12:35Speaker 4: pritis would be like n stage renal disease where you're
- 12:38Speaker 4: getting the accumulation of uremic toxins, et cetera, and probably
- 12:43Speaker 4: some changes also to sensitization of the nervous system n CKD.
- 12:50Speaker 4: It's generally a generalized parritis, but they can sometimes have
- 12:53Speaker 4: localized itching, like on the upper back where the skin
- 12:56Speaker 4: is non inflamed, and then you have colostatic parieta and
- 13:00Speaker 4: then that is also generalize but sometimes can be localized
- 13:03Speaker 4: to the palms of the hands. So I guess there's
- 13:07Speaker 4: a chronic You're thinking more systemic disease and accumulation of
- 13:13Speaker 4: indogenous substances due to you know, organ failure so you know,
- 13:18Speaker 4: liver renal. And then you're also looking at could there
- 13:22Speaker 4: be a peripheral neuropathy that is causing a localized itch
- 13:26Speaker 4: where the skin doesn't.
- 13:27Speaker 3: Look like it's having a inflammation.
- 13:32Speaker 4: And then the last cause is psychogenic, and I think
- 13:34Speaker 4: we need to appreciate that this could occur and it's
- 13:37Speaker 4: usually a diagnosis of exclusion where it's not neurogenic, it's
- 13:40Speaker 4: not neuropathic, it's not originating in the skin, which would
- 13:44Speaker 4: be like a more cutaneous cause that it could be psychogenic.
- 13:47Speaker 4: So which does occur, you know, and sometimes using an
- 13:53Speaker 4: SSRI can be helpful in those cases.
- 13:56Speaker 1: Okay, So there's lots of different causes, and remember at
- 14:00Speaker 1: your talk at ASCP there is ways to manage each
- 14:07Speaker 1: cause individually, but there's also one thing we can do
- 14:10Speaker 1: for all patients with chronic gitch. So first let's start
- 14:13Speaker 1: with what can we do for all our patients who
- 14:15Speaker 1: have chronic gitch regardless of the costs.
- 14:18Speaker 4: Yeah, so that's that's good that you brought that up,
- 14:19Speaker 4: because the discussion that we just had kind that makes
- 14:22Speaker 4: your brain itch and it's kind of overwhelming, but it's
- 14:26Speaker 4: helpful to know that there's like a common pathway in
- 14:28Speaker 4: the peripheral pathway for many of these different conditions that
- 14:33Speaker 4: cause itch. And so it's the peripheral propagation of it.
- 14:38Speaker 4: There's a hissteminergic pathway, and there's a non hissim energic pathway,
- 14:42Speaker 4: And regardless of recognizing whether histamine is involved or not,
- 14:46Speaker 4: a common receptor to both of those pathways is the
- 14:49Speaker 4: trimp receptor. And so whether we think this is mediated
- 14:53Speaker 4: by histamine in some flame skin it's an acute process,
- 14:57Speaker 4: or it's maybe a chronic condition that's neurogenic with some
- 15:01Speaker 4: peripheral involvement, regardless of it knowing those nuances, the hissim
- 15:06Speaker 4: energic peripheral pathway and the non hissam energic periperal pathway share.
- 15:12Speaker 3: The need for.
- 15:14Speaker 4: This signal, this itchy signal, to go through the trip
- 15:17Speaker 4: receptor and then the trip receptor causes an action potential
- 15:21Speaker 4: through sodium channel. So there is common pathways and common commonalities.
- 15:25Speaker 3: To both of those.
- 15:26Speaker 4: And so why this is important because using something that
- 15:30Speaker 4: causes a cooling sensation like menthol or putting lotion in
- 15:33Speaker 4: the refrigerator would activate the trip M eight receptor, which
- 15:38Speaker 4: would be common to both of those pathways. So then
- 15:40Speaker 4: that could actually reduce the itchy sensation. So that's regardless
- 15:45Speaker 4: of whether we're talking you know, neurogenic with a central
- 15:49Speaker 4: pathway but also peripheral mediators also, or we're talking about
- 15:54Speaker 4: itchy histamine mediated you know, sunburn itch, that the trip
- 16:00Speaker 4: receptor and the sodium channels are going to be common
- 16:02Speaker 4: to both of those pathways. So using something that activates
- 16:05Speaker 4: the trip receptor in a cooling sensation way, so menthol
- 16:09Speaker 4: or lotion that's cooled, and then also to block the
- 16:12Speaker 4: sodium channel, you could use a local ancetic like lytocine.
- 16:16Speaker 4: You've got to be careful with that if the itch,
- 16:18Speaker 4: in fact is more generalized, because you don't want to
- 16:21Speaker 4: bathe in this local anoscetic. But another thing is dry skin.
- 16:27Speaker 4: So dry skin, regardless of the cause, will exacerbate itching.
- 16:31Speaker 4: So another thing that happens in older adults is that
- 16:35Speaker 4: the skin may have like a greater alkaline pH and
- 16:38Speaker 4: that greater alkaline pH actually can activate proteases which then
- 16:44Speaker 4: activate the non hissiminergic pathway, and then also kind of
- 16:49Speaker 4: snowballed in with this alkaline pH and the changes of
- 16:52Speaker 4: the skin is dry skin, so kind of both of
- 16:54Speaker 4: those together can kind of activate the non hissim energic
- 16:58Speaker 4: Perferle pathway. Using ammolians and keeping the skin moisturize is
- 17:04Speaker 4: something that you should do raw patients, regardless of what
- 17:07Speaker 4: the cause of the itch might be. So we have
- 17:09Speaker 4: some tools that we can use. So lotion, refrigerated lotion
- 17:13Speaker 4: would probably be a common pathway for everybody.
- 17:17Speaker 1: Yeah, I'm glad you brought that up because I've used
- 17:21Speaker 1: that since I'm going to your town for my own kids.
- 17:24Speaker 1: Like if they have I don't know, if their eight
- 17:26Speaker 1: leg is itchy or.
- 17:27Speaker 3: Something, I'll just put.
- 17:29Speaker 1: An ice pack on it, like cool it off, you know.
- 17:32Speaker 1: Or I have told several of my nursing facilities for
- 17:36Speaker 1: patients with chronic itch they might have user in lotion
- 17:39Speaker 1: order and I'll say keep in the fridge and then
- 17:41Speaker 1: when you put it on there that can help suit
- 17:43Speaker 1: the itch along with the lotion. So I've used that
- 17:46Speaker 1: a bunch since attending your talk, and it really does work.
- 17:48Speaker 1: The cooling definitely helps the itch, and it does seem
- 17:51Speaker 1: like the warmer the room. I don't know if that's
- 17:54Speaker 1: also a thing, but my patients who have really warm rooms,
- 17:57Speaker 1: it does seem to exacerbate that itching.
- 18:00Speaker 3: A little bit.
- 18:00Speaker 1: So it's spike. Tell them, you know, maybe their room
- 18:03Speaker 1: is warm and that's making the itch worse. If they
- 18:05Speaker 1: try the cooling lotion, it'll help.
- 18:08Speaker 3: That is true.
- 18:08Speaker 4: So the if they keep a cool environment, that will
- 18:10Speaker 4: help with the itch, because warmth does worse an itch.
- 18:13Speaker 4: And that's why even though capsation also works on the
- 18:17Speaker 4: trip receptor, and that's the commonality between both those pathways,
- 18:20Speaker 4: I don't often recommend capsation because even though it may
- 18:24Speaker 4: work with repeated applications, there's also substance peas in there too.
- 18:28Speaker 4: It can cause a little warmth and that can actually
- 18:31Speaker 4: make itch worse, kind of in the beginning of trying
- 18:34Speaker 4: to use capstation.
- 18:35Speaker 3: So yeah, so definitely something with the temperature, so cool environments,
- 18:40Speaker 3: cool lotion.
- 18:41Speaker 4: Ice packs, especially when you have nerve impingement that causes
- 18:44Speaker 4: the the itching. Actually, ice packs are supposed to be
- 18:48Speaker 4: very helpful and I kind of love that idea about
- 18:52Speaker 4: sharing this information that's non pharmacological with nurses kind of
- 18:56Speaker 4: ties into the you know, the special issue I'm putting
- 18:58Speaker 4: out there that I really think it's important that pharmacists
- 19:01Speaker 4: know non pharmacological strategies because there are limitations.
- 19:05Speaker 3: To our drug therapy, you know.
- 19:06Speaker 4: And so it's like, and nurses love it, you know,
- 19:09Speaker 4: our other disciplines love it when we're able to use
- 19:11Speaker 4: somebody that's also in their wheelhouse. So so I'm glad
- 19:15Speaker 4: that you're using that because I was pretty excited. The
- 19:18Speaker 4: nurses are excited about that. The nurses that I work with,
- 19:20Speaker 4: they are excited about that tip. But I also am
- 19:22Speaker 4: pretty excited that about that tip because non pharmacological want
- 19:26Speaker 4: I'm expanding my horizons beyondrug therapy, yep.
- 19:29Speaker 1: And nurses are so amazing at treating our patients, and
- 19:32Speaker 1: so it's nice if you can give them like a
- 19:34Speaker 1: general recommendation that can help many different patients. So I
- 19:37Speaker 1: do love that about that tip as well. Okay, so
- 19:40Speaker 1: for all of our patients with ITCH, we can make
- 19:43Speaker 1: sure that their skin is getting moistened some way and
- 19:46Speaker 1: also the cooling. So let's talk about each category and
- 19:49Speaker 1: maybe like some treatment options for that category. So you
- 19:53Speaker 1: started with neurogenet causes like chronic kidney disease, what are
- 19:57Speaker 1: some treatment options for the folks who have ne genic itching?
- 20:02Speaker 4: Okay, So for neurogenic itching due to end stage renal disease,
- 20:06Speaker 4: it's generally is it's going to be you're going to
- 20:09Speaker 4: see these patients that have priority been pre treated with
- 20:11Speaker 4: an antihistamine and it didn't do anything. They're probably going
- 20:13Speaker 4: to come to you with a lot of different failed therapies.
- 20:17Speaker 4: And that's because in CKD with in advanced stages, so
- 20:21Speaker 4: either they're CKD five or SKD.
- 20:23Speaker 3: Four not yet on dialysis.
- 20:26Speaker 4: The mechanism of the paritis is central usually, so it's
- 20:31Speaker 4: due to central changes in almost like a neuropathic change
- 20:36Speaker 4: in the handling of the nervous system. There's often peripheral
- 20:40Speaker 4: mediators that accumulate. Also, like uremic toxins. There can be
- 20:44Speaker 4: accumulation of calcium and phosphorus. So there's many things that
- 20:49Speaker 4: are at play that are not mediated by histamine. So
- 20:52Speaker 4: some you know, kind of supportive measures you can do
- 20:56Speaker 4: is make sure if they're still eating food, that they're
- 20:58Speaker 4: taking phosphate binders so that they can decrease that calcium
- 21:02Speaker 4: foss product that they have, that it would accumulate these
- 21:04Speaker 4: divalent ions in the skin which can cause itching. And
- 21:08Speaker 4: then beyond that, beyond optimizing dialysis treatments and that type
- 21:13Speaker 4: of thing is we'd be using gabapentenoid. So gabapentin and
- 21:17Speaker 4: pregablin have evidence for use in reducing paritis due to
- 21:24Speaker 4: advance kidney impairment, and that's because it's likely some sort
- 21:30Speaker 4: of central sensilization that occurs, so there's changes when there
- 21:34Speaker 4: is continuous input of information to the spinal core kind
- 21:39Speaker 4: of like in pain over time, and then there's some
- 21:41Speaker 4: wind up. So gaba pentanoids work very well, and so
- 21:45Speaker 4: gama pen probably has a little bit more evidence behind
- 21:47Speaker 4: it than pregablin, but you know, kind of fair game
- 21:50Speaker 4: for either of those.
- 21:51Speaker 3: So gabapentin being a little cheaper is probably the way
- 21:54Speaker 3: to go. But you just have to be careful with
- 21:56Speaker 3: your dosing, right because this is a really really does drug.
- 22:01Speaker 4: It's going to accumulate in patients that have for renal
- 22:04Speaker 4: impairment and also removed by dialysis too, so you have
- 22:07Speaker 4: to think about timing it at bedtime. So generally the
- 22:10Speaker 4: dose is one hundred to up to three hundred three
- 22:13Speaker 4: times weekly and then falling in the evening hour, so
- 22:17Speaker 4: after dialysis and you kind of I started on one
- 22:20Speaker 4: hundred three times a week, one hundred milligrams three times
- 22:24Speaker 4: a week and falling after dialysis time, and then titraate
- 22:28Speaker 4: up based on response.
- 22:30Speaker 3: And so then the.
- 22:31Speaker 4: Pregablin dosing would be similar to a dialysis dosing of
- 22:34Speaker 4: pregabling and that actually tends to be very effective for
- 22:39Speaker 4: partis due to end stage renal disease.
- 22:42Speaker 3: Now, sometimes we try to.
- 22:45Speaker 4: Do it an indication creep with gabapentit and sometimes we
- 22:48Speaker 4: try it in other itchy conditions where it doesn't work.
- 22:51Speaker 3: So you really need to be mindful of where we're
- 22:54Speaker 3: using it.
- 22:55Speaker 4: So the greatest evidence is for end stage renal disease
- 22:57Speaker 4: patients that have chronic parritis. Now, when you have this
- 23:01Speaker 4: chronic parietis of unknown origin that's been refracturing, it's ongoing
- 23:05Speaker 4: for years, there could be some central sensitization in the
- 23:09Speaker 4: nervous system regardless of whether the patient has end sage
- 23:11Speaker 4: renal disease, for which the gabapentin would be worthwhile trying
- 23:16Speaker 4: and could be helpful to kind of being be aware
- 23:20Speaker 4: of that, because I think there can be some knowledge
- 23:24Speaker 4: that gapendon is helpful and itching, and so sometimes I
- 23:27Speaker 4: see gabapenten creeping over for uses in non neurogenic, non
- 23:34Speaker 4: central sensitization type ITCH, which is probably not where it belongs.
- 23:40Speaker 3: And then when you think.
- 23:41Speaker 4: About colostatic liver disease, you know that the mechanism is
- 23:45Speaker 4: thought to be central and peripheral, just kind of like
- 23:47Speaker 4: nstage renal diseases. And so the central mechanism is due
- 23:50Speaker 4: to imbalance of the muopioid activity and the kappa activity,
- 23:55Speaker 4: and so you will see things used like neltrexone for
- 24:00Speaker 4: this colistatic edge to kind of antagonize them MEW receptors
- 24:03Speaker 4: and kind of restore that balance. You gotta be careful
- 24:06Speaker 4: with that because if they also need opiate therapy, that's
- 24:08Speaker 4: not going to work and there's gi side effects of
- 24:11Speaker 4: it and also worsening liver disease. And then the peripheral
- 24:14Speaker 4: mechanism that you could target with with colostatic liver disease
- 24:19Speaker 4: would be like a bile acid sequestrian uh, And that's
- 24:23Speaker 4: probably usually where I would would start before throwing nail
- 24:26Speaker 4: treksone at a patient, but be like a bioacids a
- 24:29Speaker 4: question like colstyramine or sometimes cholestopol is is better tolerated,
- 24:34Speaker 4: so you're you're kind of having to go. You can
- 24:38Speaker 4: see that nowhere in there I discuss ana histamines because
- 24:40Speaker 4: they don't play a role. These are not his to
- 24:42Speaker 4: mean mediated, So you have to think about targeting a
- 24:47Speaker 4: central pathway that doesn't involve any histamine modulation. So it's
- 24:53Speaker 4: kind of, you know, a little bit of a paradigm shift.
- 24:56Speaker 4: But when you when you figure it out, it's the
- 24:58Speaker 4: patients are and the FA families are very much thankful
- 25:02Speaker 4: because pariahis and chronic partis could be as agonizing as pain,
- 25:07Speaker 4: according to some literature and to some patients.
- 25:09Speaker 1: So yeah, I have seen it where it just really
- 25:12Speaker 1: affects the patient's quality of life and then they itch
- 25:15Speaker 1: so much they get skin breakdown, and then they get
- 25:17Speaker 1: at risk for cellulitis and then all sorts of you know,
- 25:20Speaker 1: when you really got to keep up on nail care
- 25:23Speaker 1: and just you know, skin checks and things like that
- 25:25Speaker 1: for your patients with chronic itch to prevent those infections.
- 25:28Speaker 1: But it really does affect their quality of life, and
- 25:31Speaker 1: it is bothersome for these patients, and so so that
- 25:35Speaker 1: helps us with the neurogenic and the coly static causes.
- 25:40Speaker 1: So let's talk about then the neuropathic, those peripheral neuropathy,
- 25:45Speaker 1: those kind of causes of itch and how we treat those.
- 25:48Speaker 4: So generally, when you're thinking about neuropathic causes, it's usually
- 25:52Speaker 4: peripheral neuropathy. There can be central neuropathies that cause itch,
- 25:56Speaker 4: like you know, multiple sclerosis and that type of condition
- 26:01Speaker 4: can cause a neuropathic central mediated itch, but it's really rare.
- 26:05Speaker 3: So usually you're thinking peripheral.
- 26:06Speaker 4: So you're thinking about people that have post herpadic itch
- 26:09Speaker 4: following shingles, or people with peripheral diabetes with purferle diabetic
- 26:16Speaker 4: neuropathy will also have a you know, the stereotypical neuropathic pain,
- 26:20Speaker 4: but also some itch associated with it, and so how
- 26:23Speaker 4: those are managed are similar how you would manage neuropathic pain.
- 26:27Speaker 4: So using a Gama pentanoid, you also could think about
- 26:31Speaker 4: using the things that we've already previously talked about, like
- 26:34Speaker 4: the medications that work at the trip receptor like menthol
- 26:38Speaker 4: and also your local anesthetics because this is the most
- 26:42Speaker 4: of the time in prift neuropathy, it's going to be localized,
- 26:45Speaker 4: so then you can note localized itching, so you can
- 26:47Speaker 4: get away with using anesthetics without having to apply it
- 26:51Speaker 4: all over which would be problematic. So you kind of
- 26:55Speaker 4: think about there's quite a bit of similarities sometimes in
- 26:57Speaker 4: the processing of itch and pain, and so that's why
- 27:01Speaker 4: even some of the language that you use, you have
- 27:03Speaker 4: no ceoception, which is normal pain processing, and then for
- 27:08Speaker 4: it's like puerioral sception. So it's actually kind of some
- 27:12Speaker 4: overlap there in terms of the mechanism and then in
- 27:14Speaker 4: the agents that we use.
- 27:15Speaker 1: Yeah, so for the lto kine for the neuropathic pain,
- 27:19Speaker 1: do you use like a topical gel or cream or
- 27:23Speaker 1: are you talking about the lightokin patches?
- 27:26Speaker 3: So that's a good question.
- 27:28Speaker 4: So generally I would say a cream, but then you
- 27:31Speaker 4: think about if it is something localized and in an
- 27:34Speaker 4: area where a patch would be amendable to using a patch,
- 27:39Speaker 4: then I would probably prefer the patch, because if you
- 27:41Speaker 4: think about it, if it's a cream, you're going to
- 27:43Speaker 4: have to apply it very frequently and that might not
- 27:46Speaker 4: be practical. So using anything that is a topical anesthetic
- 27:50Speaker 4: and so ltokine in a patch form is topical and
- 27:53Speaker 4: not transdermal, So yes.
- 27:55Speaker 3: You could use that.
- 27:56Speaker 4: I'm glad that you brought that up because people probably
- 27:58Speaker 4: are thinking cream. But you also could use a patch
- 28:01Speaker 4: if the area of itch makes sense for using to patch.
- 28:05Speaker 1: Okay, great. I really like the patches light o Kin
- 28:08Speaker 1: patches for my older adults who have like a localized
- 28:10Speaker 1: pain because you don't get the side effects of the opioids.
- 28:14Speaker 1: And then they're over the counter now, which is really
- 28:17Speaker 1: nice because before no insurance companies would even you know,
- 28:21Speaker 1: pay for them, so you're trying to do prior offs
- 28:24Speaker 1: all the time. But now that they're available over the counter,
- 28:26Speaker 1: it makes it.
- 28:27Speaker 3: Yeah, it's a game changer with the NATL too.
- 28:30Speaker 1: Yeah.
- 28:30Speaker 3: Absolutely. Okay, So the last cost.
- 28:33Speaker 1: Here we haven't talked about is that psychogenic causes of
- 28:36Speaker 1: chronic itch, which is that diagnosis of exclusion probably, but
- 28:40Speaker 1: how do we treat that?
- 28:42Speaker 4: So that tends to be similar to how you would
- 28:44Speaker 4: manage other you know, psychiatric issues, is using your your
- 28:50Speaker 4: your psychopharmical therapy. So SSRIs and I kind of like
- 28:54Speaker 4: the idea.
- 28:55Speaker 3: Of using secually because if you.
- 28:57Speaker 4: Look at some of the other literature for neurogenic causes
- 29:01Speaker 4: that generalized it. Circuline also plays a role, can play
- 29:04Speaker 4: a role in you know, due to itching due to
- 29:07Speaker 4: n sage real disease or colocetic liver disease, and also psychogenic.
- 29:11Speaker 4: So in case maybe you miss something, miss some other
- 29:13Speaker 4: underlying cause, then that SSRI, particularly seculing would be would
- 29:19Speaker 4: be the go to.
- 29:19Speaker 3: So that's probably how I would manage it.
- 29:23Speaker 4: If it's safe to initiate an SSRI in in that
- 29:28Speaker 4: particular individual, you might have to use redirecting or distraction
- 29:32Speaker 4: or something of that nature. But again it could also
- 29:35Speaker 4: feel good to use lotion that's been cool, then that
- 29:38Speaker 4: could maybe be helpful for the psychogenic ish also, So
- 29:41Speaker 4: a lot of our tools kind of go across the continuum,
- 29:45Speaker 4: and we're not really talking about anahistamine.
- 29:48Speaker 3: So now I don't want to say we can't ever
- 29:50Speaker 3: use it in an.
- 29:50Speaker 4: A histamine if it has the histamine the wheel and
- 29:53Speaker 4: flair reaction and it's in flame skin and it's very
- 29:58Speaker 4: clearly due to an a Q issue, so a sunburn,
- 30:03Speaker 4: a drunk hypersensitivity, an insect bite, you know, hives.
- 30:08Speaker 3: It's either a cute somebody to get a cute and.
- 30:10Speaker 4: Chronic hives and those conditions are definitely responsive danta histamines.
- 30:15Speaker 3: So not completely voted off the island.
- 30:18Speaker 4: But if you're going to do an antaistamine, you actually
- 30:20Speaker 4: use second generation anta histamines. They are thought to have
- 30:25Speaker 4: equal efficacy to a first generation, so there's no reason
- 30:27Speaker 4: you'd have to do diphenhydromine. You could definitely do second generation.
- 30:33Speaker 4: And my preference kind of is for satarizine because I
- 30:36Speaker 4: can pull out this study that showed that seterazine actually
- 30:39Speaker 4: was equivalent to hydroxyzine in a city of a q Itch,
- 30:43Speaker 4: which is good because a lot of the folks I
- 30:46Speaker 4: work with assume for some reason hydroxyine is like where
- 30:49Speaker 4: you go to after benadryl doesn't.
- 30:51Speaker 3: Work, And I'm like, no, no, not necessarily.
- 30:55Speaker 4: You can even used saterrasine, which I would have similar
- 30:57Speaker 4: efficacy to hydroxyzine with lesser side effect burden.
- 31:02Speaker 1: So yeah, I like that because a lot of I
- 31:04Speaker 1: agree with you. A lot of my providers also seem
- 31:08Speaker 1: to go toward hydroxyzene and it really does make my
- 31:11Speaker 1: patients tired, you know, they're just sleepy during the day
- 31:15Speaker 1: when they're on it. So I like the idea of
- 31:17Speaker 1: satyrs need better myself too. So you're saying, if it's
- 31:20Speaker 1: mediated by histamine, you would see something on the skin
- 31:25Speaker 1: that would show it would be needed by histamine.
- 31:27Speaker 4: Probably generally the skin would be inflamed and it's trickering
- 31:31Speaker 4: because like you said, people are scratching, they're getting secondary infections,
- 31:35Speaker 4: and it's hard to tell, but generally it should have
- 31:39Speaker 4: the traditional histamine flare and wheel type of high looking
- 31:42Speaker 4: picture that would be suggestive of a histamine mediated pathway.
- 31:47Speaker 4: So then some people say, well, the benadro worked and
- 31:49Speaker 4: we didn't see any of the skin changes that you're
- 31:52Speaker 4: talking about, Well, the ben droll probably worked.
- 31:55Speaker 3: If it worked and.
- 31:56Speaker 4: There wasn't the traditional histamine reaction, it work through sedation,
- 32:01Speaker 4: and so that's where you know. It sounds like, yeah,
- 32:04Speaker 4: I know it worked, but that's nothing that's necessarily reason
- 32:07Speaker 4: I want it to work, because any symptom will be
- 32:11Speaker 4: somewhat suppressed through sedation. If you have less conscious awareness
- 32:15Speaker 4: of an itch, of a nausea of pain that through sedation,
- 32:20Speaker 4: then symptoms will be relieved. But that not might not
- 32:23Speaker 4: necessarily be the way we want to do it. Maybe
- 32:26Speaker 4: you've reserved it for a bedtime us.
- 32:28Speaker 3: If it really.
- 32:29Speaker 4: Disturbs sleep, but you will sometimes see that you know,
- 32:32Speaker 4: oh the handa hissamine did work, but it.
- 32:35Speaker 3: Was probably through sedation.
- 32:38Speaker 4: So so if you really want to know if it's
- 32:40Speaker 4: really Anna Hissamy mediated, then use something that doesn't have
- 32:43Speaker 4: any sedation, potentially like lraratity and if it didn't work,
- 32:47Speaker 4: then it wasn't hiss to me mediated. So and sincere
- 32:52Speaker 4: thing has a little bit of a blood bloborry Berry penetration,
- 32:55Speaker 4: so maybe a little bit of sedation, So that way
- 32:57Speaker 4: you kind of get a little best to both worlds
- 32:59Speaker 4: there I'm sleeping is maybe and then.
- 33:03Speaker 3: The antihistamine effect. So it's a pro buy in. Yeah,
- 33:08Speaker 3: that's a pro tip right there.
- 33:09Speaker 1: I like that because when I do have patients on
- 33:12Speaker 1: hydroxysne and they say it help, I've always wondered, like, well,
- 33:16Speaker 1: is it helping because of the sedation or the anti histamine.
- 33:18Speaker 1: But I like that switch them to a lratitine or
- 33:21Speaker 1: a non city in the antistamine, see if it's still working.
- 33:24Speaker 1: And if you switch them and it's not working anymore,
- 33:26Speaker 1: you know it's from the sedation and not the anti
- 33:28Speaker 1: histamine effects.
- 33:29Speaker 3: Yes, I like that.
- 33:31Speaker 1: Okay, So I do have one more question about gaba
- 33:33Speaker 1: pin because you know, I do think it can be
- 33:36Speaker 1: really helpful for cotigage. So when you start them off
- 33:39Speaker 1: at the one hundred milligrams three times a week after dialysis,
- 33:43Speaker 1: how long do you give it to be effective? And
- 33:46Speaker 1: at that point do you increase the dose if it's
- 33:48Speaker 1: not effective or do you say, you know, at what
- 33:50Speaker 1: point do you say gaba pinin is not going to
- 33:52Speaker 1: work for your itch, let's stop it.
- 33:55Speaker 4: So that's a really good question because we think about
- 33:57Speaker 4: in pain that we usually have to not usually we
- 34:00Speaker 4: always have to titrate to a range between nine hundred
- 34:05Speaker 4: but generally eighteen hundred milligrams to the max dos of
- 34:08Speaker 4: thirty six hundred milligrams per day before we're seeing an
- 34:11Speaker 4: improvement in pain, and that can take two months if
- 34:16Speaker 4: you're diligent about it. Now, now, we do tend to
- 34:19Speaker 4: see an earlier response when we're using gibapensant for itch,
- 34:22Speaker 4: and I think it's primarily because these patients have and
- 34:25Speaker 4: stage a renal disease and so we're kind of hitting
- 34:29Speaker 4: target doses for acting on those calcium invated calcium calcium
- 34:34Speaker 4: meanium voltage gated calcium channels. There you go volted gated
- 34:37Speaker 4: calcium channels, we're kind of getting where we need to
- 34:41Speaker 4: go in terms of targeting those channels sooner because of
- 34:45Speaker 4: the end stage renal disease, if that makes sense. So
- 34:48Speaker 4: there's kind of less of a titration response and GEMBA
- 34:52Speaker 4: penton when you first initiate it has the transient drowsiness
- 34:57Speaker 4: that does improve over time, So there's a little a
- 35:00Speaker 4: little bit of sedation a little bit.
- 35:02Speaker 3: That's why you dose it at bedtime.
- 35:03Speaker 4: That probably gives us an increased perception that it's helpful
- 35:07Speaker 4: with the patients early on while we kind of get
- 35:11Speaker 4: to the dose that we need to go, so I
- 35:13Speaker 4: usually say within one to two weeks. Again I'm a pendant.
- 35:16Speaker 4: In my experience, has been helpful because we're thinking that
- 35:18Speaker 4: target dose for actually acting on our bultishcated calcium channels
- 35:23Speaker 4: is much lower than if they had normal radar function
- 35:26Speaker 4: and then the sedative piece in there.
- 35:28Speaker 3: So but that should hopefully be transient. If it's persistent,
- 35:31Speaker 3: then we need to do something about it because then.
- 35:32Speaker 4: We have to ask ourselves what is worse for the patient,
- 35:36Speaker 4: the ish or not being able to engage with their
- 35:38Speaker 4: family and kind of reduce even further. Sometimes we've had
- 35:41Speaker 4: patients just on one hundred milligrams twice a week, so
- 35:45Speaker 4: kind of working with you know, their preferences itch versus
- 35:50Speaker 4: daytime sleepiness. So yeah, that's a good question, and I
- 35:54Speaker 4: don't have a great answer for you, except that I
- 35:56Speaker 4: do see that the titration schedule is much tighter because
- 36:00Speaker 4: our target doses are much much lower.
- 36:04Speaker 1: Yeah, that is helpful because I agree sometimes when you
- 36:08Speaker 1: use gallopin and for paint, it feels like it takes
- 36:10Speaker 1: forever to get to that target dose. But if the
- 36:12Speaker 1: target dose is small and you see an effect in
- 36:14Speaker 1: one to two weeks, that's great.
- 36:17Speaker 3: Okay.
- 36:17Speaker 1: So for a pharmacist who want to learn more on
- 36:19Speaker 1: this topic and who want some good resources for their
- 36:23Speaker 1: patients that have chronic pritis, where would you recommend they
- 36:27Speaker 1: go to look?
- 36:29Speaker 4: So that someone needs to write a book for us,
- 36:32Speaker 4: because when I put together this presentation, it was really
- 36:36Speaker 4: really hard to get resources together that was just all
- 36:40Speaker 4: in one one place. So I really kind of struggled
- 36:44Speaker 4: with that in terms of finding.
- 36:46Speaker 3: A good resource. So I would say there are a
- 36:49Speaker 3: few textbooks that are a little bit older that I
- 36:51Speaker 3: think do put it together completely.
- 36:54Speaker 4: It didn't have much of the a lot of the
- 36:55Speaker 4: mechanism pieces that I wanted, so I had to go
- 36:57Speaker 4: elsewhere and look at some journal articles for that.
- 37:01Speaker 3: But it's from Oxford.
- 37:02Speaker 4: So sometimes Oxford Publishing publishes little mini books on various
- 37:07Speaker 4: topics related to palliation. And so they have a book
- 37:11Speaker 4: called Partis in Advanced Disease, and it's from two thousand
- 37:15Speaker 4: and four, so it's a little bit data, but we
- 37:17Speaker 4: really haven't gone very far, so there might be a little.
- 37:20Speaker 3: Bit less discussion of the gamma pentanoids, but.
- 37:22Speaker 4: I still believe it's in there in some way, so
- 37:26Speaker 4: that textbook is helpful. I actually got this other book
- 37:30Speaker 4: it's like called Parritis from Springer, and it was very detailed,
- 37:34Speaker 4: very technical, very you know, this mediator does this, So
- 37:37Speaker 4: I don't necessarily recommend that unless you're really trying to
- 37:40Speaker 4: go home and draw out the pathways for parritis. Other
- 37:44Speaker 4: books that could be helpful resources the Palliative Care Consultant Book,
- 37:50Speaker 4: which is you know, for hospice and paliative care.
- 37:52Speaker 3: It does have a chapter on parritis, but I would
- 37:55Speaker 3: say to get it all in one.
- 37:58Speaker 4: Place, all the information in one place, so I haven't
- 38:01Speaker 4: been super lucky.
- 38:04Speaker 3: There is some in terms of guidelines.
- 38:06Speaker 4: We don't even really have American guidelines that are focused
- 38:09Speaker 4: on paraitis, so I actually had to go to European
- 38:11Speaker 4: guidelines and they have several guidelines that are mostly focused
- 38:16Speaker 4: acute and chronic urncardia or however you say it, hives,
- 38:20Speaker 4: and that did have helpful information about.
- 38:22Speaker 3: The nuances with antihistamines.
- 38:25Speaker 4: Another resource if you want more information about antahistamines in general,
- 38:30Speaker 4: I think the APHA book, the Non Prescription Drug Handbook,
- 38:35Speaker 4: I think that has recently been updated, was a good
- 38:38Speaker 4: resource for that. But again, like I had to piece
- 38:41Speaker 4: meal things to really put together a whole picture, so
- 38:44Speaker 4: there's probably not one comprehensive resources, a bunch of pieces together.
- 38:50Speaker 4: And then just your own clinical experience with it, because
- 38:54Speaker 4: it's a lot of the literature isn't high quality, right,
- 38:57Speaker 4: we're looking at case reports, retrospective. Your own clinical experience
- 39:02Speaker 4: is probably going to inform your practice too.
- 39:04Speaker 1: Yeah, And I feel like just learning from you and
- 39:07Speaker 1: from talks like this where you know you have a
- 39:09Speaker 1: patient come to the counter or you see a patient
- 39:12Speaker 1: in your facility and they're talking about it and you
- 39:15Speaker 1: see it's been long term. You know, it can at
- 39:17Speaker 1: least make you think, oh, you know, maybe get a
- 39:21Speaker 1: pin and I should look in to get a pen
- 39:22Speaker 1: for this, or you know, is this psychogenic? Do they
- 39:25Speaker 1: need start to so at least gets you thinking about
- 39:28Speaker 1: potential other causes and if nothing else, put the lotion
- 39:31Speaker 1: in the fridge and tell them to grab an ice pack.
- 39:33Speaker 1: You know. So just little things like that can always
- 39:36Speaker 1: help pharmacists, you know, expand our knowledge base and at
- 39:39Speaker 1: least get us thinking in a direction that we hadn't
- 39:42Speaker 1: thought to think before.
- 39:43Speaker 3: So exactly. Yep, Well, this.
- 39:45Speaker 1: Has been absolutely amazing. I always love learning from you
- 39:49Speaker 1: and I'm excited to learn from you again at the
- 39:51Speaker 1: next ASCP conference coming up here. But in the meantime,
- 39:54Speaker 1: where can people find you?
- 39:59Speaker 3: So at LinkedIn?
- 40:00Speaker 4: I'm on LinkedIn, so if you want to touch base
- 40:03Speaker 4: with me, LinkedIn would be the way to go, or
- 40:07Speaker 4: maybe my editor email, so that's JPPCP dot editor in
- 40:13Speaker 4: chief at gmail dot com. But I would say probably
- 40:17Speaker 4: the quickest way to get a hold of me is
- 40:19Speaker 4: LinkedIn because I do have the notifications on my phone,
- 40:22Speaker 4: so I will get a notification and to search my name,
- 40:25Speaker 4: and that's the easiest way to probably find me and
- 40:28Speaker 4: find things that I'm doing currently.
- 40:32Speaker 3: And if you want to collaborate on anything, I am.
- 40:34Speaker 4: I am open to it. Geriatric Pallative Care. Always looking
- 40:37Speaker 4: for new projects and new things to you know, expand
- 40:43Speaker 4: my toolkit.
- 40:45Speaker 1: I love it. You're amazing.
- 40:46Speaker 3: Thank you so much, and thank you.
- 40:48Speaker 1: Listener, so I appreciate you. Have a great day.